H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced HR+ HER2 Negative Breast Carcinoma
Interventions: DRUG: Enituzumab injection+Abesili tablets+Anastrozole tablets
Sponsor: Tianjin Medical University Cancer Institute and Hospital